Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Jul 1, 2013 (Vol. 33, No. 13)

Harnessing the Clinical Power of Single Cells

  • New Normalization

    Along those same lines, researchers have also run into challenges translating standard data normalization methods for bulk nucleic acid preparations to single-cell data.

    For instance, using “housekeeping” genes to normalize qPCR expression data does not make sense at the single-cell level.

    In addition to expression within single cells, Dr. Flynn is interested in studying variations in expression among cells. Being able to discern technical variance from biological variance is a major concern for many of the amplification strategies prior to assay measurement, Dr. Flynn says.

    Dr. Flynn and his colleagues are using large expression datasets from nanofluidic qPCR arrays and homogenous reference samples from entire cell populations to normalize data. This approach is somewhat analogous to microarray formats that normalize the signal from each probe spot to the array itself combined with spiked in controls. Overall, this strategy has been fairly successful in validating the single-cell measurements.

    Another concern when analyzing single-cell data is that many standard statistical approaches are unusable because much of the single-cell data violates the basic assumptions within these tests.

    “The all-too popular Student’s t-test is not appropriate for gene expression comparisons at the single-cell level. We are taking the stance that data analysis must be non-parametric and should be the new standard in single-cell analysis,” Dr. Flynn says.

    Data interpretation can indeed be difficult. According to Cincinnati Children’s Hospital’s Dr. Potter, the limitations relate to existence of fewer than ten transcripts per expressed gene, and gene expression occurring in a burst mode, not as a steady state process. “We have made much progress, but there is still considerable room for improvement,” he says.

    As Dr. Flynn at the Buck Institute puts it: “What I think will be of broad interest to the biotech community is how single-cell biology will change our approach to the development of disease treatments,” he says. “What is really an unknown at the moment is how diseases progress on a cell-by-cell basis.”

    While it is established that cancers can begin with a single cell escaping cell cycle control, it is not so clear if the progression of other maladies come from similar stochastic changes. Single-cell analysis is a potent tool in identifying not only the disease pathogenesis, but also in the development of targeted cell therapies. Current approaches are based on highly sensitive single-cell tests to diagnose diseases prior to the development of clinical symptoms.

    Further, single-cell analysis allows for sample sizes of hundreds if not thousands of individual cells in order to detect disease in a normal cell haystack.

    Overall, single-cell technology will drive both the sensitivity and specificity of future clinical assays up, Dr. Flynn says.

  • Clinical Utility

    Click Image To Enlarge +
    A comparison of immunophenotyping technologies: Cytology is best for analysis of a few cells, but is limited in multiplexing due to fluorescence spillover. Flow cytometry is very useful for multiplexing up to 10–15 proteins, but requires a large number of cells and multiplexing reduces single cell sensitivity. According to Genome Data Systems, its label-free CytoSnap™ method will allow highly multiplexed analysis at a single-cell resolution.

    Of course, academic investigators aren’t alone in their enthusiasm about the clinical promise of single-cell analysis.

    Several companies, like Genome Data Systems, also seek to harness the power of cellular heterogeneity as potential biomarkers.

    “Our vision is that in a few years every clinical trial will include single-cell analysis,” says the firm’s founder and president Rajan Kumar, M.D., Ph.D.

    Genome Data Systems’ CytoSnap™ tool can be used to perform multiplexed single-cell protein expression analysis in a wide range of biological samples. Monitoring changes in protein expression could have clinical utility in terms of diagnostic biomarkers.

    “CytoSnap can simultaneously detect as well as characterize at the molecular level rare cells such as circulating tumor cells (CTCs) in blood and disseminated tumor cells in bone marrow biopsies,” Dr. Kumar says.

    The technology, which has been used in highly multiplexed analysis for label-free screening of CTCs in a patients’ blood, has the potential to analyze a single-cell sample for 100 or more proteins. Beyond identifying and characterizing the expression patterns of individual CTCs in blood samples from breast cancer patients, “using our CytoSnap technology, we have compared protein expression patterns of several breast cancer cell lines cultured in vitro and samples from xenograft tumors,” Dr. Kumar adds.

    “We distinguished luminal, Her2+, and basal-like cells from breast cancer cell lines based on differential protein expression profiles with greater than 95% sensitivity and more than 99% specificity,” he explains. “CytoSnap functions by measuring transient cell interactions with immobilized antibodies in a microfluidic channel. Expression of the proteins of interest reduces cell velocities on patches coated with cognate antibodies compared with a pooled IgG patch as a control.”

    According to Dr. Kumar, the technology is also nondestructive: “Essentially unaltered cells can be isolated for additional analysis, for example, using RT-PCR.” He points to pharmacogenomics as an entry point for the technology’s use in personalized medicine, though he notes that potential applications range from diagnostic assays to patient stratification in clinical trials, measuring response to treatment, and development of companion diagnostics.

    “In the future, we plan to seek FDA approval for the instrument and for clinically relevant companion diagnostic tests in collaboration with academic researchers, CROs, and pharmaceutical companies,” says Dr. Kumar.

Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »